Affimed company info

What does Affimed do?
Affimed NV (NASDAQ:AFMD) is a biopharmaceutical company deeply engaged in the development of immunotherapies to improve treatment outcomes for patients with cancer. Leveraging its proprietary ROCK® (Redirected Optimized Cell Killing) platform, Affimed NV designs and advances a pipeline of innate cell engagers that aim to harness the power of the body's own immune system. The company's lead projects focus on various hematologic and solid tumor indications, reflecting its commitment to bringing novel cancer treatments from concept through clinical trials to commercialization. With operations that span from early-stage research to advanced clinical trials, Affimed NV drives forward with the objective of transforming cancer treatment paradigms to offer hope and life-extending solutions to patients worldwide.
Affimed  company media
Company Snapshot

Is Affimed a public or private company?

key
Ownership
Public

How many people does Affimed employ?

people
Employees
76

What sector is Affimed in?

pie chart
Sector
Health Care

Where is the head office for Affimed ?

location pin
Head Office
Heidelberg, Germany

What year was Affimed founded?

founded flag
Year Founded
2000
What does Affimed specialise in?
/Cancer Immunotherapies /Antibody Development /NKcell Engagers /Biopharmaceutical Company /Clinical Trials /Healthcare Services

What are the products and/or services of Affimed ?

Overview of Affimed offerings
AFM13, an innate cell engager targeting CD30-positive malignancies.
AFM24, an EGFR-targeting innate cell engager for solid tumors.
AFM28, an innovative approach for treating acute myeloid leukemia.
Partnered with Genentech for discovering new cancer immunotherapies.
Collaboration with Roivant Sciences to develop and commercialize AFM32, aiming at multiple solid tumor targets.
Development of AFM26, a B cell maturation antigen (BCMA) targeting therapy for multiple myeloma.

Who is in the executive team of Affimed ?

Affimed leadership team
  • Dr. Andreas  Harstrick M.D.
    Dr. Andreas Harstrick M.D.
    Interim CEO, Chief Medical Officer & Member of Management Board
  • Dr. Wolfgang  Fischer Ph.D.
    Dr. Wolfgang Fischer Ph.D.
    MD, COO & Member of Management Board
  • Ms. Denise  Mueller
    Ms. Denise Mueller
    Chief Business Officer & Member of Management Board
  • Prof. Melvyn  Little
    Prof. Melvyn Little
    Founder & Consultant
  • Mr. Michael  Wolf
    Mr. Michael Wolf
    Head of Finance & Administration
  • Mr. Alexander  Fudukidis
    Mr. Alexander Fudukidis
    Head of Investor Relations & Director of Investor Relations
  • Mary Beth Sandin
    Mary Beth Sandin
    Vice President of Marketing & Communications